Immunotherapy combo fails to show promise in advanced thyroid cancer trial

NCT ID NCT03753919

First seen Mar 13, 2026 · Last updated Apr 25, 2026 · Updated 9 times

Summary

This study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with advanced thyroid cancer that had stopped responding to standard treatments. The goal was to see if the combination could slow or stop cancer growth. The trial was stopped early, and results were not strong enough to recommend this approach as a new standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC THYROID PAPILLARY CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • Complejo Hospitalario Universitario de Vigo (CHUVI)

    Vigo, 36036, Spain

  • Hospital Clínic Barcelona

    Barcelona, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital General Universitario Morales Meseguer

    Murcia, Spain

  • Hospital Provincial de Castellón

    Castellon, Valencia, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Instituto Catalán de Oncología de Hospitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Instituto Valenciano de Oncología

    Valencia, 46009, Spain

  • MD Anderson Cancer Center

    Madrid, 28033, Spain

Conditions

Explore the condition pages connected to this study.